DaBai XiaoBai Rhinology Files IPO Prospectus: Empowering Grassroots Clinics with Integrated Diagnosis, Treatment, and Education Solutions for Nasal Diseases

“We are a very down-to-earth rhinology project,” said Lu Sheng, co-founder of the Dabai Xiaobai Rhinology Project, expressing considerable pride as he introduced his venture to VCBeat.

“Our target clients are the most grassroots medical institutions, including village doctors, township health centers, private community clinics, and community health service centers. In particular, private community clinics are not affected by policies such as the ‘Two-Invoice System’; their decisions are driven primarily by their own operational and development needs, with procurement being highly market-oriented.”

Wuhan Dabai Xiaobai Rhinology Co., Ltd. (hereinafter referred to as “Dabai Xiaobai Rhinology”) primarily empowers primary care physicians through intelligent technologies, enhancing their diagnostic and treatment capabilities to provide more convenient and precise services for patients with nasal disorders.

Nasal disorders are common conditions; for instance, the common cold is medically termed acute rhinitis. Rhinitis has a high prevalence rate. According to the latest data from the International Association of Otolaryngology, the global incidence of rhinitis ranges from approximately 10% to 40%, with a trend of year-on-year increase. In China, there are around 300 million rhinitis patients, and this number is growing at an annual rate of 3%. In addition to common symptoms such as nasal congestion, runny nose, and sneezing, severe cases can lead to respiratory obstruction, resulting in headaches, dizziness, and memory decline, which are particularly detrimental to the learning and intellectual development of adolescents. Patients with rhinitis not only suffer from the distress of impaired nasal breathing but may also experience a series of concurrent symptoms, including headaches. Furthermore, rhinitis and sinusitis can trigger serious complications such as cor pulmonale and asthma, and increase the risk of nasopharyngeal cancer and sinus malignancies.

In addition, nasal disorders include sinusitis, allergic rhinitis, and nasal polyps, among others. These conditions significantly impair patients’ quality of life, with the treatment of allergic rhinitis posing a major challenge for the medical community both in China and abroad.

A significant proportion of patients seen at primary care clinics, approximately 30% to 40%, suffer from nasal disorders or related conditions. While some present with severe symptoms requiring urgent treatment, others have mild symptoms and often neglect prevention and daily healthcare. Nasal diseases are prone to acute exacerbations during seasonal changes, severely impacting patients' quality of life. Although the nasal care market is substantial and demand for treatment services is high, the limited diagnostic and therapeutic capabilities of primary healthcare institutions result in suboptimal nasal disease management.

Dabai Xiaobai ENT’s independently developed Intelligent Diagnostic Decision Support System for Otorhinolaryngology empowers primary care physicians and medical institutions through a cloud-based SaaS information management platform, a decision support system, and a rapid learning module. Currently in its Version 1.0, the system enables primary care physicians to obtain diagnostic results by simply entering patients’ chief complaints and symptoms, thereby facilitating effortless diagnosis. At this initial stage, the decision support system provides comprehensive assessments based on patients’ clinical manifestations and medical history. In the future, it will incorporate image recognition capabilities to achieve greater intelligence.

When discussing the competitive advantages of Dabai Xiaobai ENT, Lu Sheng stated that the niche market currently chosen by the company has, strictly speaking, no competitors, because other manufacturers adopt a product-centric industrial mindset, while Dabai XiaobaiRhinology“Holistic Solutions” for Primary Care Physicians and “User-Centric Thinking” Centered on Patients.

The rhinology program features a four-in-one comprehensive therapy, which includesSmart Examination——Intelligent Endoscopic Diagnosis and Treatment System for the Nose, Featured Therapy——Nasal Irrigation Interventional Therapy,Traditional Chinese Medicine Conditioning System— Weifulu Oral Solution, Compound Menthol Oil Nasal Drops <in-house preparations of over 100 hospitals including West China Hospital and Tongji Hospital>, etc.,Health Education—Brand exposure and science popularization education via self-media and community platforms, etc. From accurate diagnosis to treatment plans and chronic disease management, the entire suite of solutions is delivered to primary care physicians, empowering them to provide more precise treatments and deliver full-course patient care.

In terms of business,Dabai XiaobaiRhinologyRevenue is generated primarily through therapeutic ENT products, including Weifulu Oral Solution, Compound Menthol Oil Nasal Drops, imported medical devices, and related consumables. Software and hardware equipment and systems are provided free of charge to primary healthcare institutions.and provide comprehensive support to medical institutions in operating specialized rhinology departments, enhance the operational and management capabilities of primary care medical institutions, and help partner clients build competitive advantages in specialized rhinology treatment within their service coverage areas.

To better deliver rhinology treatment technologies and services, Dabai Xiaobai Rhinology’s self-built outpatient clinic has also entered the implementation phase.Dabai Xiaobai ENT aims to create a leading brand for ENT medical services in China and establish itself as the premier chain of ENT healthcare providers by innovatively integrating pharmaceuticals, medical devices, diagnostic testing, and internet-based tools in collaboration with primary care institutions.

In terms of market promotion, Dabai Xiaobai Rhinology adopts a full-category academic marketing model centered on “Internet + specialized rhinology.” Unlike traditional manufacturers, the company places academic promotion at the strategic core, rather than treating it merely as a sales tactic.

Core Components of the Full-Portfolio Academic Marketing Model:

1、All Categories: Centered on “patient disease,” integrating products and projects across the entire care journey, including diagnosis (medical devices and equipment), treatment (pharmaceuticals and health supplements), rehabilitation (hardware devices), and internet-based tools.

2、Academic Education: Focusing on the prescription habits of primary care physicians, we leverage scientifically rigorous clinical solutions and appropriate technologies as key instruments, deliver systematic academic training to primary care practitioners through specialists, and facilitate continuous information dissemination via medical representatives.

3、Co-Building Rhinology: Centered on rhinology, by integrating clinical experts, healthcare management specialists, chronic rhinologic disease management programs, and upstream third-party vendors, we provide comprehensive support to primary healthcare institutions in developing nasal disease treatment services or building rhinology departments, thereby helping them establish their own distinctive features and core competitiveness.

Unlike traditional manufacturers that initially target the national market, Dabai XiaobaiRhinologyIt first establishes a local model market, then leverages this to penetrate the national market, ultimately achieving full coverage across China.For example, the company first established a model market in Wuhan and then replicated it nationwide. Practice has proven that this operational model has achieved favorable results. Currently, the company’s technical output covers thousands of primary healthcare institutions across provinces such as Hubei, Hebei, Shandong, Chongqing, and Sichuan; regarding departmental co-construction, 13 departments have been jointly established, with 483 additional departments in the pipeline for potential collaboration.

The company has established a Medical R&D Center, leveraging its self-built rhinology outpatient clinics as a foundation to attract mid-career and young otolaryngologists from tertiary hospitals. It has also engaged renowned experts in otolaryngology, pediatrics, and traditional Chinese medicine (TCM) as medical advisors to integrate multi-party resources for the development of the center. The functions of the Medical R&D Center are twofold: first, to identify clinically appropriate technologies for rhinological diseases that are most suitable for implementation at the primary care level, and to develop TCM treatment protocols for complex and refractory rhinological conditions; second, to support the company’s academic promotion strategy by training primary care physicians in rhinology, assisting primary healthcare institutions in the collaborative management of chronic rhinopathy patients. More importantly, the center continuously collects clinical treatment feedback from primary care physicians to optimize and update academic promotion strategies, iterate the company’s internet-based products, and upgrade therapeutic products, thereby creating a closed-loop system for academic promotion.

Wang Xiangjun, General Manager of Dabai Xiaobai ENT Clinic, stated that compared to ophthalmology, dentistry, and medical aesthetics, the field of otolaryngology remains a blue ocean market, with significant potential for major brands to emerge in this niche sector. “Dabai Xiaobai” is the company’s registered trademark, derived from Baymax, the intelligent healthcare robot featured as one of the protagonists in the animated film Big Hero 6. Wang Xiangjun himself is an expert in grassroots medical marketing, having conducted numerous public lectures and corporate training sessions. He has accumulated extensive expertise in controlled sales strategies for primary care clinics and innovative Internet-plus operations. With strong foundations in practical experience, theoretical innovation, and well-established channels and networks within the grassroots healthcare market, the team is confident in its ability to excel in this venture and create a groundbreaking linear brand.

It is reported that Dabai Xiaobai ENT Clinic is seeking RMB 3 million in angel-round financing to fund product development and offline promotion.